C9067: Gallium ga-68, dotatoc, diagnostic, 0.01 mci
C9067 is a HCPCS Level II code for gallium ga-68, dotatoc, diagnostic, 0.01 mci. It belongs to the Outpatient Prospective Payment System section. Whether Medicare pays it depends on the coverage rule below.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q4-Oct. This states Medicare’s position on the code, not on your particular claim.
Medically Unlikely Edits: units per day
The most units of C9067 Medicare will pay on one date of service. Bill more on a single line and it is denied. The limit is not the same in every setting, so the row that matters is the one matching the claim you are building.
- practitioner
- 500 units MAI 3: Date of Service Edit: Clinical · Prescribing Information
- outpatient
- 500 units MAI 3: Date of Service Edit: Clinical · Prescribing Information
The adjudication indicator decides whether exceeding the limit is worth appealing at all: MAI 1 is a line edit you can support with documentation, MAI 3 is a date-of-service edit that is also appealable, and MAI 2 is absolute, no documentation overrides it. CMS MUE 2026Q4.
The CMS record for C9067
- Long descriptor
- Gallium ga-68, dotatoc, diagnostic, 0.01 mci
- Short descriptor
- Gallium ga-68 dotatoc
- Added
- October 1, 2020
- BETOS
- O1E
- Pricing indicator
- 53: Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
Berenson-Eggers Type of Service: CMS's own analytic grouping.
Statute.
Codes adjacent to C9067
HCPCS has no hierarchy: related items simply sit next to each other in the numbering. If C9067 is not quite right, the correct code is very often within a few positions of it.
- C9059Injection, meloxicam, 1 mgterminated
- C9060Fluoroestradiol f18, diagnostic, 1 mciterminated
- C9061Injection, teprotumumab-trbw, 10 mgterminated
- C9062Injection, daratumumab 10 mg and hyaluronidase-fihjterminated
- C9063Injection, eptinezumab-jjmr, 1 mgterminated
- C9064Mitomycin pyelocalyceal instillation, 1 mgterminated
- C9065Injection, romidepsin, non-lyophilized (e.g. liquid), 1mgterminated
- C9066Injection, sacituzumab govitecan-hziy, 2.5 mgterminated
- C9068Copper cu-64, dotatate, diagnostic, 1 millicurieterminated
- C9069Injection, belantamab mafodontin-blmf, 0.5 mgterminated
- C9070Injection, tafasitamab-cxix, 2 mgterminated
- C9071Injection, viltolarsen, 10 mgterminated
- C9072Injection, immune globulin (asceniv), 500 mgterminated
- C9073Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseterminated
- C9074Injection, lumasiran, 0.5 mgterminated
- C9075Injection, casimersen, 10 mgterminated